Haplotype Labs develops SaaS technology for population genetics, simplifying complex analysis workflows. This platform significantly reduces sequencing costs while accelerating research timelines by eliminating the need for bespoke software pipelines. The core offering enables researchers to predict, detect, and prevent disease using advanced polygenic risk models.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Genomic sequencing is often expensive, and analyzing the resulting data can be slow and require custom software pipelines, creating bottlenecks in research and clinical applications. These challenges limit the accessibility and scalability of genomic analysis for disease prediction, detection, and prevention.
Solution
Haplotype offers a SaaS platform designed to significantly reduce the cost and complexity of genomic sequencing and analysis. The platform streamlines workflows and eliminates the need for custom software pipelines, accelerating the process of genetic analysis. By leveraging polygenic risk models, the platform enables more efficient prediction, detection, and prevention of diseases.
Target Audience
The primary customers are researchers and clinicians seeking to reduce the costs and time associated with genomic sequencing and analysis for disease prediction and prevention.
Features
- Reduces sequencing costs by 50% to 90%
- Utilizes polygenic risk models to predict, detect, and prevent diseases
- Accelerates genetic analysis by streamlining workflows
- Eliminates the need for custom software pipelines